Laboratoire en 1ère ligne contre les maladies neurologiques

« Une technologie de rupture déclinable dans de nombreuses pathologies neurologiques »

> Communiqués de presse

Inclusion of the first patient in the phase II clinical study that aims to test THN102 in patients affected by narcolepsy
27/10/2016
Télécharger le PDF (260 Ko)

Theranexus has obtained an orphan drug designation from the FDA for THN102 in the treatment of narcolepsy
04/10/2016
Télécharger le PDF (428 Ko)

Theranexus and its partners receive support from the FUI (French Inter-ministry Fund) for their project, Cx-COG
20/09/2016
Télécharger le PDF (149 Ko)

Theranexus reaches its primary endpoint in the proof of concept trial of THN102 in Excessive Daytime Sleepiness (EDS)
17/05/2016
Télécharger le PDF (174 Ko)

Preclinical results published in the specialist medical journal Sleep, Phase II entry of THN102
30/03/2016
Télécharger le PDF (111 Ko)

Inclusion of the first subjects in the efficacy study on the treatment of sleep disorders
19/10/2015
Télécharger le PDF (556 Ko)

Success of phase 1 trial on the safety of a new treatment of narcolepsy and launch of efficacy studies
15/07/2015
Télécharger le PDF (567 Ko)

Theranexus lève avec succès 3,6 M€ en amorçage
17/11/2014
Télécharger le PDF (147 Ko)